There were no serious side effects in the participants enrolled for the phase 1 trial of Covaxin, according to the results published in The Lancet

If allowed to go ahead, this would be the first trial of any coronavirus vaccine in Bangladesh and could give the densely-populated country of more than 160 million faster access to the shot for mass use

Bharat Biotech is developing the intranasal vaccine in partnership with the Washington University School of Medicine and US-based vaccine maker Ocugen

Government think tank NITI Aayog's members along with top medical experts have requested the people eligible for vaccination not to fall for rumours on safety. They added that minor adverse effects are common and should not deter people from inoculation

The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) on Tuesday recommended Bharat Biotech's intranasal vaccine for conducting phase 1 clinical trials for the coronavirus

People adopting a \"wait and watch\" approach, lack of communication and glitches in CoWin app are the major reasons why only 53 per cent people got the COVID-19 shots on the first day in Delhi, experts said on Sunday

Coronavirus vaccination drive: Covaxin has asked its recipients to sign a consent form. The form also states that in case of adverse effects, the recipient would be compensated

Ten of these states have already received 20,000 doses of Covaxin, while Assam has so far got 12,000 doses

Company shall be liable for all adversities as per CDSCO/Drugs and Cosmetics Act/DCGI policy/approval, says government's purchase order with vaccine makers

As of now, the pre-condition for any vaccine to be implemented in India is that you have to do a bridging trial, said Niti Aayog member VK Paul who also heads National Expert Group On Vaccine Administration for COVID-19 (NEGVAC)

The pre-prints or preliminary reports of research work related to Covaxin, which are yet to be peer-reviewed are already posted on pre-print servers like bioRxiv, medRxiv and Research Square

The Central government on Saturday said India will launch its COVID-19 vaccination drive from January 16, with priority to be given to nearly three crore health care and frontline workers

Coronavirus vaccination drive: The letter alleged irregularities and ethical violations in the conduct of the clinical trial of Covaxin by the People's College of Medical Sciences & Research Centre, Bhopal

The drug firm has manufactured the affected lot at its Kurkumbh facility in Maharashtra and then supplied to its New Jersey-based subsidiary

Bharat Biotech revealed that one of the participants for Phase III trials passed away on December 21, 2020, and the death was reported to the People's College of Medical Sciences and Research Centre by the son of the deceased

Bharat Biotech has sent a proposal to the Drugs Controller General of India (DCGI) to seek its approval for trials of a nasal vaccine against COVID-19. The firm recently introduced Covaxin vaccine in India, which has been approved for emergency use in the country. The trials for nasal vaccine will be conducted on at least 30-45 volunteers above the age of 18 years at four trial sites in the country, including Bhubaneswar, Pune, Nagpur and Hyderabad. Watch the video for more.Also Read: Phase 1 vaccination to cost govt Rs 21,000-27,000 crore: SBI Research

Bharat Biotech chairman Krishna Ella says this nasal vaccine will revolutionise Indian vaccine making capabilities and help it leapfrog along with Europe, the US and China

(For) all our vaccines, we are looking at right now..(we) are targeting 2-8 degree because our logistics are worked out on that basis and we are working on that, DBT secretary Renu Swarup said at a press briefing

Bhopal gas activist Rachna Dhingra through a tweet on Sunday had alleged that poor and vulnerable residents of gas affected communities were herded by the People's University with a promise of Rs 750

Talking to BusinessToday.In, Dr. Krishna Ella, Chairman and MD, Bharat Biotech, said the trial would take around four months and if the regulator gives quick permission the company might start with the clinical trial